This study is exploring whether a special type of scan, called 68-Ga DOTATATE PET/MRI, can help doctors better diagnose and manage certain brain tumors. These tumors include meningioma, esthesioneuroblastoma, hemangioblastoma, and medulloblastoma, among others, that are "somatostatin receptor positive" (meaning they have specific markers on their cells). Researchers want to see if this scan can provide more useful information than standard MRI, especially in telling the difference between a tumor growing back and changes from previous treatments. You might be able to join if you are 18 to 100 years old and have a diagnosis of meningioma with suspected recurrence, or another somatostatin receptor positive brain tumor. The study aims to evaluate the clinical benefit of this scan over a long period, up to 10 years. The current recruitment status is unclear.

Study design

This is an interventional study planning to enroll 200 participants. It is not specified if it is randomized or blinded.

What's involved

If you have meningioma and are having surgery, you would undergo a PET scan at the same time as your standard MRI before surgery. The study also involves longitudinal assessment for up to 10 years.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed with longitudinal assessment for up to 10 years to evaluate clinical benefit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.